{
  "ticker": "SNT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970425",
  "id": "02970425",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250718",
  "time": "0828",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250718/pdf/06lx9pf76rh57d.pdf",
  "summary": "### Summary of ASX Announcement:  \n\n- **Clinical Trial Initiation**: Phase 1b/2 AZALOX trial commenced for **amsulostat (SNT-5505)** in combo with **5-Azacitidine** for **MDS/CMML** patients.  \n- **Trial Structure**:  \n  - **Phase 1b**: Safety/dose escalation (3-12 patients).  \n  - **Phase 2**: Efficacy in 30 patients at selected dose.  \n- **Key Catalyst**: Trial progression (Phase 1b completion) could de-risk development pipeline.  \n- **Funding/Support**: Backed by **German Cancer Aid**; conducted across **9 German centers**.  \n\n*No other material trading or capital markets information identified.*",
  "usage": {
    "prompt_tokens": 2298,
    "completion_tokens": 159,
    "total_tokens": 2457,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-17T22:45:32.368129"
}